Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLE-100 (oral esketamine) as adjunct therapy in major depressive disorder
NCT04103892Phase 2Completed
- Sponsor
- Clexio Biosciences
- Start
- Sep 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of CLE-100 in major depressive disorder (MDD) (4 arms), sponsored by Clexio Biosciences. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 29 days. Started Sep 2019; status: completed.
02
Drugs
CLE-100
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04103892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04103892.